Disease: Myalgia eosinophilia associated with tryptophan
- 1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant
- 1,1'-Ethylidenebis[L-tryptophan], a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome, suppresses mRNA expression of hypothalamic corticotropin-releasing hormone in Lewis (LEW/N) rat brain
- 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro
- 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
- A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome
- A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms
- A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan)
- Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan
- Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats
- Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations
- Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake
- AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?
- An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan
- Analytical characterization of peptide contaminants of L-tryptophan
- Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities
- Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome
- Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome
- Central nervous system involvement in the eosinophilia-myalgia syndrome
- Chronic immune activation in the eosinophilia-myalgia syndrome
- Comparative histopathologic evaluation of animal studies: murine studies with L-tryptophan and constitutents
- Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome
- Current differential diagnosis of hypereosinophilic syndrome
- Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism
- Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan
- Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia
- EBT, a tryptophan contaminant associated with eosinophilia myalgia syndrome, is incorporated into proteins during translation as an amino acid analog
- Effect of L-tryptophan products on function of human eosinophils: investigation of the causal mechanisms of eosinophilia myalgia syndrome associated with L-tryptophan products
- Effects and side effects associated with the non-nutritional use of tryptophan by humans
- Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic
- Eosinophilia myalgia syndrome
- Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases
- Eosinophilia-myalgia syndrome and fasciitis with an active alveolitis
- Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan
- Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan
- Eosinophilia-myalgia syndrome in Germany: an epidemiologic review
- Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan
- Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements
- Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia
- Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia
- Eosinophilia-myalgia syndrome: a long-term follow-up study
- Eosinophilia-myalgia syndrome: lessons for public health researchers
- Eosinophilia-myalgia syndrome. Natural history in a population-based cohort
- Eosinophilic cholecystitis as a possible late manifestation of the eosinophilia-myalgia syndrome
- Eosinophilic fasciitis associated with L-tryptophan ingestion
- Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome
- Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique
- Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome
- Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan
- Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome
- Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome
- Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome
- Head and neck manifestations of eosinophilia-myalgia syndrome
- Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms
- Increased activity of the alpha 1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome
- Increased type I collagen gene expression in L-tryptophan associated eosinophilia-myalgia syndrome skin fibroblasts
- L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis
- L-tryptophan-induced eosinophilia-myalgia syndrome associated with primary cutaneous malignant fibrous histiocytoma and extraabdominal desmoid tumor
- L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia
- L-Tryptophan: Biochemical, nutritional and pharmacological aspects
- Litigation over illness associated with tryptophan is possible
- Long-term follow-up of patients with diffuse fasciitis and eosinophilia associated with L-tryptophan ingestion
- Neurocognitive dysfunction in the eosinophilia-myalgia syndrome
- Neuromuscular diseases with eosinophilia
- On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome
- On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome
- Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats
- Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome
- Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome
- Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres
- Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan
- Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome
- Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome
- Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness
- Restrictive cardiomyopathy associated with the eosinophilia-myalgia syndrome
- Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome
- Safety evaluation of dried L-tryptophan fermentation product in Sprague-Dawley rats
- Safety of 5-hydroxy-L-tryptophan
- Separation and isolation of trace impurities in L-tryptophan by high-performance liquid chromatography
- Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome
- Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome
- Structural characterization of contaminants in commercial preparations of melatonin by on-line HPLC-electrospray ionization-tandem mass spectrometry
- Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome
- Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome
- Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome
- Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan
- Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan
- Tetrahydro-beta-carboline-3-carboxylic acids and contaminants of L-tryptophan
- The Importance of Quality Specifications in Safety Assessments of Amino Acids: The Cases of l-Tryptophan and l-Citrulline
- The many faces of scleroderma
- The tryptophan-associated eosinophilia-myalgia syndrome. A clinical follow-up of 8 patients
- Toxic oil syndrome: the perspective after 20 years
- Toxicology and safety study of L-tryptophan and its impurities for use in broiler feed
- Toxicology and safety study of L-tryptophan and its impurities for use in swine
- Treatment of depression and sleep disorders. Significance of serotonin and L-tryptophan in pathophysiology and therapy
- Tryptophan and 5-hydroxytryptophan for depression
- Tryptophan and 5-hydroxytryptophan for depression
- Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico
- Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome
- Tryptophan toxicity--time and dose response in rats
- Tryptophan-induced lung disease: an immunophenotypic, immunofluorescent, and electron microscopic study